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Abstract.  Studies with various thrombin derivatives 
have shown that initiation  of cell proliferation by 
thrombin requires two separate types of signals:  one, 
generated by high affinity interaction of thrombin or 
DIP-thrombin (alpha-thrombin  inactivated at ser 205 of 
the B chain by diisopropylphosphofluoridate) with 
receptors and the other,  by thrombin's  enzymic activ- 
ity.  To further study the role of high affinity thrombin 
receptors in initiation,  we immunized mice with whole 
human fibroblasts and selected antibodies that blocked 
the binding of t25I-thrombin to high affinity receptors 
on hamster fibroblasts. One of these antibodies,  TR-9, 
inhibits  from 80 to  100% of t25I-thrombin binding,  ex- 
hibits an immunofluorescent pattern indistinguishable 
from that of thrombin bound to receptors on these 
cells, and selectively binds solubilized thrombin recep- 
tors.  By itself, TR-9 did not initiate DNA synthesis 
nor did it block thrombin initiation,  but TR-9 addition 
to cells in the presence of alpha-thrombin,  gamma- 
thrombin (0.5 gg/ml), or PMA stimulated thymidine 
incorporation up to threefold over controls.  In all 
cases, maximal  stimulation was observed at concentra- 
tions of TR-9, ranging  from  1 to 4  nM corresponding 
to concentrations  required to inhibit from 30 to  100% 
of ~25I-thrombin binding.  These results demonstrate 
that the binding of the monoclonal antibody to the 
alpha-thrombin  receptor can mimic the effects of 
thrombin's high affinity interaction with this receptor 
in stimulating  cell proliferation. 
H 
IGHLY purified  thrombin  initiates  proliferation  of 
fibroblastic  cells in serum-free medium without ad- 
dition of other growth factors (14, 21, 46--48, 60), ini- 
tiates proliferation  of mammalian  lens epithelial  cells (50), 
and stimulates DNA synthesis in spleen cells (22). Thrombin 
also acts synergistically  with other growth factors to stimu- 
late proliferation  of hamster fibroblasts  (23) and human en- 
dothelial  cells (33, 59). More recendy, thrombin  has been 
shown to act as a chemoattractant  to stimulate cell migration 
(4-6). Therefore, thrombin may play a significant role in sev- 
eral aspects of wound healing  when presented to cells after 
tissue injury. 
Early studies demonstrated that the action of thrombin at 
the cell surface is sufficient to initiate cell proliferation  (13, 
15)  and  that  this  thrombin  interaction  appears  to  involve 
specific high affinity receptors (14). A number of studies have 
been carried out to characterize  these receptors and the inter- 
action  of thrombin  with  fibroblasts.  Photoaffinity  studies 
with fibroblasts have shown active thrombin and proteolyti- 
cally inhibited  thrombin cross-linking  to molecules of ap- 
proximate 50,000 (17) and  150,000 (43, 56) Mr. HPLC size 
exclusion  and  HPLC  immunoaffinity  purification  of the 
thrombin receptor also indicate that fractions retaining throm- 
bin receptor binding activity contain molecules correspond- 
ing to  150,000, 105,000, and 55,000 Mr (Frost, G.  H., and 
D. H. Carney, manuscript in preparation).  Thus,  it is likely 
that the intact receptor may have multiple  subunits or a pro- 
teolytically labile region similar to the insulin receptor (25). 
Studies  with  indirect  immunofluorescence  microscopy, 
immunocytochemistry,  and ultrastructural  autoradiography 
have shown that these receptors, unlike receptors for epider- 
mal growth-factor  (EGF) I and insulin,  are clustered on the 
surface of cells before thrombin binding  (7,  11,  12). These 
receptors and the clusters appear to be excluded from coated 
pits (12). Furthermore,  125I-thrombin bound to these recep- 
tors is not rapidly internalized  and  degraded (7).  Instead, 
degradation  of thrombin occurs after thrombin complexes to 
protease-nexin  (PN) and is internalized  via PN receptors 
which are not involved in thrombin  mitogenesis  (2, 3, 38). 
Thus, thrombin receptors,  interaction of thrombin with these 
receptors,  and the transmembrane signals generated  by this 
interaction  may be somewhat different  from that observed 
with other growth factors. 
Consistent  with thrombin's  enzymic role as a serine pro- 
tease,  thrombin  mitogenesis  appears to require both high 
affinity receptor occupancy and enzymatic cleavage of the 
1. Abbreviations used in this paper: DIP-thrombin, alpha-thrombin inacti- 
vated at ser 205 of the B chain by diisopropylphofluoridate; DV, Dulbecco- 
Vogt  modified  Eagle's  medium;  EGF, epidermal  growth  factor;  PN, 
protease-nexin. 
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lytically inactive DIP-thrombin (alpha-thrombin  inactivated 
at ser 205 of the B chain by diisopropylphosphofluoridate) 
binds to thrombin receptors on mouse embryo and hamster 
cells as well as native alpha-thrombin,  but by itself does not 
initiate cell proliferation (29). Likewise, gamma-thrombin, 
which retains enzymic activity but not the potential for high 
affinity occupancy, does not by itself initiate cell prolifera- 
tion.  In the presence of receptor-saturating  concentrations 
of DIP-thrombin,  however,  gamma-thrombin  initiates  cell 
proliferation to levels approaching maximal stimulation by 
alpha-thrombin (20). Thus, both receptor occupancy and en- 
zymic cleavage and the signals generated by each appear to 
be required to stimulate cell proliferation (18, 20). 
The use of intact alpha-thrombin and these thrombin de- 
rivatives has facilitated analysis of the role of receptor oc- 
cupancy and proteolysis in relation to transmembrane signal 
events that may be involved in mitogenesis. In this system, 
phosphoinositide turnover (19), Ca  ++ mobilization (Carney, 
D.,  et al.,  manuscript  in preparation),  and  stimulation  of 
Na+/H  § antiport  (52,  53)  all  appear  to  be  stimulated  by 
alpha-  or gamma-thrombin  but not by DIP-thrombin  (18). 
Since PMA can also stimulate Na+/H  + antiport (9) we post- 
ulated that the activation of protein kinase C may be impor- 
tant in mediating thrombin's enzymic effects on these cells. 
We recently showed that the addition of PMA to ceils in com- 
bination with DIP-thrombin  stimulates DNA synthesis and 
cell proliferation  as well as the combination of DIP- and 
gamma-thrombin (31). Thus, it appears that PMA activation 
of protein kinase C can mimic the enzymic effects of gamma- 
thrombin  in  completing  a  mitogenic  signal.  In  contrast, 
receptor occupancy by DIP- or alpha-thrombin stimulates a 
transient  increase in cAMP, but cAMP derivatives cannot 
stimulate  cell  proliferation  in  combination  with  gamma- 
thrombin or PMA (32). This suggests that high affinity inter- 
action ofthrombin with its receptor may generate conforma- 
tional changes in the receptor and/or additional signals which 
are required for thrombin mitogenesis. 
To more fully define the thrombin receptor responsible for 
these  signals  and  to understand  the  nature  of the  signals 
generated by high affinity receptor interaction, we have pre- 
pared monoclonal antibodies to the thrombin receptor.  We 
now show that these antibodies initiate DNA synthesis in the 
presence of esterolytically active thrombin or PMA. 
Materials and Methods 
Materials 
Human alpha-thrombin of high purity (•3,000  NIH U/ltg) was supplied by 
Dr. J. W. Fenton II (New York Department of Health, Albany, NY). Unless 
otherwise stated, all common chemicals were purchased from Sigma Chem- 
ical Co., St. Louis, MO. Plastic tissue culture dishes were obtained from 
Coming Glass Works,  Coming  Science Products,  Coming,  NY.  Na~2SI 
(100 Ci/mmol, 17 Ci/ltg free iodine) was purchased from Amersham Corp., 
Arlington Heights, IL. 
Cell Cultures 
Human fibroblasts used to immunize mice were prepared from cells migrat- 
ing out of minced human foreskin tissues, and primary cultures of fibro- 
blasts were prepared from 9-13-d-old embryos of Swiss outbred mice, as 
previously described (16). NIL cells are an established strain of Syrian ham- 
ster fibroblasts provided  by  Frank  Solomon  (Massachusetts  Institute of 
Technology, Cambridge, MA). Faza rat hepatoma cells were given to us by 
Gerald Fuller (University of Alabama, Birmingham, AL). These cells were 
maintained and grown in a  1:1 mixture of Dulbecco-Vogt modified Eagle's 
medium and Ham's F-12 medium (DV/Ft2;  Gibco, Grand Island, NY) sup- 
plemented with 10% calf serum or, in the case of Faza cells, FBS (Hyclone 
Laboratories,  Logan,  UT),  penicillin (100  U/ml), and streptomycin (100 
ttg/ml), in a humidified atmosphere of 5 % CO~ in air at 37~ 
Nonproliferating quiescent cultures of these cells were prepared by sub- 
culturing stock cells from 100-mm dishes with an EDTAltrypsin solution 
(PBS containing 0.2% EDTA and 0.05% trypsin) and plating them onto 24- 
well culture plates or glass coverslips in DV/F12 medium  supplemented 
with 10% calf serum or FBS at 6.5  ￿  104 cells/em  2. After cell attachment, 
the medium was removed and the cells were rinsed with serum-free DVtF~2 
medium and incubated in this serum-free medium for 48 h to bring the cells 
to a quiescent G~/Go arrested slate (24). 
Immunization Procedure 
BALB/c  mice  were  injected  intraperitoneally  with  107  human  foreskin 
fibroblasts two times at 4-wk intervals. 2 mo after the last injection, the mice 
received a booster injection and were killed 3 d  later for the cell fusion. 
Hybridization and Selection of  Hybridomas 
Spleen cells from the immunized mice were fused with P3 myeloma cells 
(36) at a 5:1  ratio following the procedure of Galfrc et al.  (28) and using 
41%  (vol/vol) polyethylene glycol  1500 as the fusing agent. Hybrid cells 
growing  in hypoxanthine/aminopterin/thymidine selective medium  were 
initially screened for their ability to inhibit ~25I-thrombin binding and for 
their pattern of binding to the surface of formaldehyde-fixed mouse embryo 
cells. Cells from selected clones were subcloned and initially cultured in 
DV/F,2  medium supplemented with  17%  horse serum (Irvine Scientific, 
Santa Anna, CA). To reduce the complication of serum factors that bind to 
thrombin receptors (8), promising clones were cultured in 17% Nu Serum 
(Collaborative  Research,  Inc.,  Waltham,  MA) or  injected  into isogenic 
BALB/c mice for ascites production and antibody purification. 
Purification  of  Antibody  from Ascites Fluid 
TR-9 IgM monoclonal antibodies were purified using a modification of the 
procedure described by Bouvet et al.  (10).  Briefly, ascites fluid was cen- 
trifuged at 10,000 g for 30 min to remove particulate material. The precipi- 
tate from a 30-50% ammonium sulfate precipitation was dissolved and ap- 
plied to a Sephacryl S-200 column and eluted in PBS. Fractions containing 
IgM located in the void volume by a solid phase radioimmunoassay using 
~I-goat  anti-mouse  IgM  (Cappel  Scientific  Div.,  CooperBiomedical, 
Inc., Malvern, PA) were pooled, concentrated, dialyzed, and applied to a 
second Scphacryl S-200 column equilibrated in 0.005 M phosphate buffer, 
pH 8.0, and eluted with 0.05 M phosphate buffer, pH 8.0, containing 1.7 M 
NaCI.  IgM antibodies precipitate in this low salt column and elute after 
resolubilization with increasing salt concentration. Thus the majority of ma- 
terial elutes in the void volume while the IgM fraction elutes as a second 
peak. The purity of the IgM fraction at the last stage of the purification was 
>90-95%  based on analysis of SDS-polyacrylamide gels (37) and reverse 
phase HPLC. 
Immunofluorescence Microscopy 
Secondary cultures of fibroblasts were plated on glass coverslips (1  ￿  104 
cells/era  2) and prepared for immunofluorescence staining as described by 
Carney (11). The fibroblasts were fixed in 3% formaldehyde and incubated 
with either thrombin (60 ng/ml) and afffinity-purified  rabbit antithrombin or 
mouse ascites diluted in 15 mM Hepes buffered DV medium (pH 7.4) con- 
taming 0.5% BSA. The cells were then stained with anti-mouse or anti- 
rabbit rhodamine-labeled antibody (Cappel Scientific Div., CooperBiomed- 
ical, Inc.). 
Iodination of  Thrombin and TR-9 
Purified thrombin was iodinated by the lactoperoxidase method as described 
previously (12,  14), Purified TR-9 IgM antibodies (150 t,  tg) were iodinated 
in the presence of 20 ttg Iodo-gen (1,3,4,6-tetrachloro-3a,6a-diphenylgly- 
couril; Pierce Chemical Co., Rockford, IL). The labeled antibodies were 
separated from unreacted iodide by gel filtration in a  Sephadex G-25  M 
prepacked column (Pbarmacia, Uppsala,  Sweden) that had been washed 
and equilibrated with PBS containing 5%  BSA (wt/vol) and eluted with 
PBS. The specific activity of ~2~I-TR-9 was  1  x  106 cpm per ttg protein. 
The Journal of Cell Biology, Volume 105,  1987  2552 Binding Assays 
J251-Thrombin  binding to fibroblasts  in the absence or presence of mono- 
clonal antibodies was measured with nonproliferating  cultures of NIL ham- 
ster cells in 24- or 48-well plates at a density of "06 ￿  104 cells/cm  2 as pre- 
viously described (14). The medium on the cells was changed to binding 
medium  (serum-free  DV  medium  containing 0.5%  BSA  buffered  with 
15 mM Hepes at pH 7.0). The cells were equilibrated at 23~  for 30 min 
and the medium was changed to binding medium containing  various concen- 
trations of antibody.  The cells were preincubated with antibody for 2 h at 
230C, after which J25I-thrombin  was added (final concentration, 30 ng/ml) 
and the cells incubated for another 2 h at 23~  The assay was terminated 
by quickly rinsing the cells four times with cold PBS. The cells were dis- 
solved in 1 ml of 0.5 N NaOH and the total radioactivity  was determined. 
Nonspecific binding was measured as the radioactivity bound to cultures af- 
ter incubation in binding medium containing excess unlabeled thrombin (3 
~tg/ml). Specific binding was determined by subtracting nonspecific binding 
from total  radioactivity  bound to cultures.  Total and nonspecific  binding 
were  each  measured  on  duplicate  cultures.  Specific  binding normally 
represents ,080% of the total t25I-thrombin bound in control wells.  Under 
these  binding conditions,  SDS  gel  electrophoresis shows  little,  if any, 
125I-thrombin-PN complex formation.  Thus, under these conditions, spe- 
cific ~251-thrombin  binding primarily represents thrombin interaction with 
its high affinity receptors. 
~25I-TR-9 binding to fibroblasts  in the presence or absence of alpha- 
thrombin  was  measured  in  the  same  manner  as  described  for  ~2Sl- 
thrombin. 
Immunoa~nity Chromatography 
Purified TR-9 monoclonal antibody (2 mg) was covalently linked to cyano- 
gen bromide-activated Sepharose CL 4B (10 ml) (Pharmacia Inc., Piscata- 
way, NJ). The TR-9-Sepharose  was washed, blocked with 1 M glycine, and 
then incubated overnight with a mixture of membrane proteins that had been 
extracted from fibroblasts with PBS containing 10 mM (3[3 cholamidopro- 
pyl]  dimethylammonio-l-propanesulfonate),  25 % glycerol,  1 mM dithio- 
threitol, 1 mM EDTA and various protease inhibitors, i.e., antipain (20 I~g/ 
ml), aprotinin (0.1 trypsin inhibitor U/ml), leupeptin (20 ~tg/ml), pepstatin 
(20 lxg/ml) and phenylmethylsulfonyl  fluoride  (1  raM). After incubation, 
the affinity column was washed and bound protein was eluted with 0.1 M 
citrate/500 mM NaCI buffer, pH 2.0. The eluted protein fractions were then 
adsorbed to plastic in 24-well clusters overnight at 37~  and tested for their 
ability to specifically  bind t~I-thrombin as described above. 
SDS-PAGE Analysis 
Cell surface proteins that bound to TR-9-Sepharose  were analyzed by elec- 
trohoresis in polyacrylamide  slab gels (5% acrylamide) with 0.1% SDS in 
0.1 M Tris-acetate buffer, pH 8.2, in both gel and electrode buffer (58). After 
electrophoresis,  the gels were stained with 0.05 % Coomassie Brilliant Blue 
R-250 (Bio-Rad Laboratories,  Richmond, CA) dissolved in 50% 2-propanol 
and destained  with 10% acetic acid/10% 2-propanol. 
Measurement of  DNA Synthesis 
The effects of TR-9 on DNA synthesis, either alone or in combination with 
gamma-thrombin,  were  determined by  measuring the  incorporation of 
methyl-[3H]thymidine  (TdR;  ICN Pharmaceuticals,  Irvine, CA) during a 
30-rain incubation for 23.5-24  h  after addition of TR-9  and/or alpha- 
thrombin, gamma-thrombin, or PMA. After incubation, the cells were ex- 
tracted and rinsed with cold 10% TCA. The acid-precipitable  material was 
dissolved  overnight in 0.5 ml KOH (0.5N) at 23"C.  0.25 rrd HC1 (IN) was 
added and the solution was counted in 10 ml of scintillation fluid (Beckman 
ReadySolv-HPb;  Beckman Instruments, Houston,  TX). 
Results 
Selection and Characterization of  Monoclonal 
Antireceptor Antibodies 
To better characterize the high affinity  thrombin receptor and 
define its role in mediating the mitogenic effect of thrombin, 
we prepared monoclonal antibodies to this receptor. Since a 
purified receptor  was  unavailable,  mice  were  immunized 
by injection of whole human foreskin fibroblasts. After the 
fusion,  supernatants  from  ,~200  hybridoma clones  were 
screened for inhibition of ~25I-thrombin binding to mouse 
embryo or NIL hamster cells. Approximately 30 clones ex- 
hibiting inhibition over control supernatants were expanded 
and further analyzed by comparing the immunofluorescent 
staining pattern of the antibodies to that of thrombin on fixed 
cells. As shown in Fig. 1, thrombin binding to both HF ceils 
originally injected into mice for immunization (Fig.  1 A), 
Figure 1.  Immunofluorescent staining of thrombin and TR-9 monoclonal antibodies on human and NIL hamster cells. Coverslip cultures 
of human fibroblasts (A) or NIL hamster cells (B and C) were fixed in 3% formaldehyde and incubated with thrombin (A and B) followed 
by polyclonal rabbit anti-thrombin (B) or TR-9 monoclonal antibody (C). Cells were stained with anti-mouse or anti-rabbit rhodamine-la- 
beled second antibody and photographed as described in Materials and Methods.  Bar, 20 I~m. 
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Figure 2.  Inhibition  of  t25I- 
thrombin  binding to hamster 
fibroblasts  by purified  TR-9 
IgM antibodies.  The binding 
of 30 ng/ml of nsI-thrombin 
to live (o) and 3 % formalde- 
hyde-fixed (￿9  hamster fibro- 
blasts was inhibited by increas- 
ing  concentrations  of  TR-9 
IgM. 
and NIL hamster fibroblasts (Fig.  1 B) can be visualized 
with antithrombin polyclonal antibodies as a distinct pattern 
of dots, each •400  nm in diameter. Previous studies have es- 
timated that each of these clusters contains from 200 to 1,000 
thrombin receptors (11, 12). It should be noted that this stain- 
ing pattern  is quite different from that of EGF or insulin 
which appear to initially bind to diffuse receptors (35, 41, 
44). Furthermore, other receptors that cluster before ligand 
binding  of molecules  such  as  low  density  lipoprotein  or 
asialoorosomucoid have dusters in coated pits which appear 
to be larger and generally concentrated in these cells near the 
nucleus (1,  12, 30, 45, 57). 
Of the 30 clones analyzed for their  immunofluorescent 
staining pattern,  19 had diffuse or negative staining patterns 
suggesting that their inhibition of ~25I-thrombin binding may 
have been due to nonspecific blocking of receptors or interac- 
tion with thrombin before binding.  11 clones had dotlike pat- 
terns of various intensities.  Of these, four appeared to have 
large perinuclear dots characteristic of binding to receptors 
in coated pits and seven exhibited binding patterns similar to 
the binding of thrombin to its receptor. One of these, an IgM 
producer  designated  TR-9,.  exhibited  strong  growth,  high 
binding competition, and consistent dotlike staining pattern 
indistinguishable  from that of thrombin bound to its recep- 
tors (Fig.  1 C). 
The diffuse binding or binding to large perinuclear dots 
observed with some clones that blocked thrombin binding 
may have represented binding  to protease nexin or to PN 
receptors. The dot pattern of TR-9 binding, however, appears 
to be quite characteristic of high affinity thrombin receptor 
binding.  Previous studies have shown that high concentra- 
tions of heparin that block thrombin-PN complex binding to 
PN receptors (2) have no effect on thrombin binding to its 
high affinity receptors and does not affect thrombin binding 
to the clustered receptors visualized by immunofluorescence 
microscopy (11). Thus, the dot pattern observed with TR-9 
(Fig.  1  C)  is  characteristic  of thrombin  binding  to  high 
affinity receptors and not to PN or to PN receptors. 
Further evidence for the specificity of TR-9 was obtained 
after subcloning, production ofascites fluid, and purification 
of TR-9. As shown in Fig. 2, pretreatment of NIL cells (live 
or  prefixed  with  3%  formaldehyde  in  parallel  to the  im- 
munofluorescence binding) with purified TR-9 inhibits L~5I- 
thrombin binding up to 80%  with half-maximal  inhibition 
occurring at a concentration of --2 nM. Under these binding 
conditions,  where  cells  are  rinsed  free  of  conditioned 
medium  containing  protease  nexin,  previous studies  have 
failed to detect 125I-thrombin-PN  complexes contributing to 
the specific binding. In addition, in several experiments we 
Table L  Comparison of 125I-Thrombin and 125I-TR-9 
Binding to Thrombin Receptor-positive  and-negative Cells 
TR-9  Thrombin-  TR-9- 
Cell type  immunobloning*  binding sites$  binding sites$ 
NIL cells  +  4.0  x  10  ~  4.1  ￿  105 
BII-C cells  +  5.0  ￿  105  4.6  ￿  105 
Faza cells  -  Not detectable  2.3  x  103 
* Nonproliferating  cultures  of NIL hamster  cells,  BI I-C cells,  or Faza rat 
liver  hepatoma cells  in  100-mm tissue  culture  dishes  (4  ￿  106 cells)  were 
solubilized in SDS-PAGE sample buffer and subjected to electrophoresis in 5% 
polyacrylamide gels as described in Materials and Methods. The separated pro- 
teins  were then transferred  from the gel  into nitrocellulose according to the 
method of Towbin et al. (55). After transfer,  TR-9-binding sites were visual- 
ized with the Immun-blot (GAR-HRP) assay kit (Bio-Rad Laboratories). 
$ These numbers were obtained from the Scatchard type analysis of the bind- 
mg of various  concentrations  of ~2Sl-thrnmbin (15-500  ngtml)  or u~I-TR-9 
(0.25-8 nM) to nonproliferating cultures of NIL hamster cells,  BI I-C cells, 
or Faza  rat liver  hepatoma cells in 24-well plates at a density of ~6  x  104 
cells/cm 2 as described previously  (14). 
have observed up to 100% inhibition of the specific binding 
of thrombin to NIL cells by TR-9,  indicating  that at these 
thrombin  concentrations  all binding  is to a  single specific 
receptor recognized by TR-9. 
To further  establish that  TR-9 recognizes  the thrombin 
receptor, we iodinated purified TR-9 and compared its bind- 
ing to different cells with that of 125I-thrombin. Table I sum- 
marizes the estimations of total binding sites from Scatchard 
plots for three different cell types. As shown, there appears 
to be a positive correlation between immunoblotting to puta- 
tive thrombin receptor bands on SDS gels, number of bind- 
ing sites for thrombin,  and the number of binding sites for 
TR-9. Both NIL hamster fibroblasts and Bll-C's, an estab- 
lished line of mouse embryo cells initially selected for high 
numbers of thrombin binding sites (54), have ",,4-5  x  1@ 
binding sites for both thrombin and purified TR-9. In con- 
trast, Faza cells, an established rat hepatoma cell line (40), 
show negative immunoblotting of putative thrombin recep- 
tors and have less than a  few thousand  thrombin or TR-9 
binding sites. Thus, direct binding of TR-9 correlates with 
binding  of  125I-thrombin.  Furthermore,  in  both  NIL  and 
Bll-C cells, unlabeled thrombin partially inhibits binding of 
l~5I-labeled TR-9 (data not presented). Thus, it seems likely 
that TR-9 recognizes an epitope on the thrombin  receptor 
near, but perhaps not identical to, the domain responsible for 
high affinity thrombin binding. 
Table II. Binding of 125I-Thrombin to TR-9-purified 
Fractions Adsorbed to Plastic 
Specific t'-~l- 
Preparation  thrombin binding* 
NIL cell total extract 
TR-9 affinity column 
Nonadsorbed material 
Adsorbed material (removed with 
citrate/NaCI) 
cpm/l~g protein 
33.0  5-  0.2 
46.25:8 
439.3  :t:  252 
* Radioactivity is expressed as cpm per l~g protein initially added to each well. 
Each value represents the mean of triplicate determinations plus or minus the 
standard deviation. 
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column. Eluted proteins from the TR-9-Sepharose were subjected 
to SDS-PAGE as described in Materials and Methods. Before elec- 
trophoresis, the samples were boiled in Tris-acetate buffer for 5 min 
in the presence of 0.1% 13-mercaptoethanol.  Molecular mass stan- 
dards were applied to lanes A and B. Lanes C-F contain increasing 
concentrations of pooled material eluted from the column. 
If  TR-9 binds an epitope on thrombin receptors on cell sur- 
faces, one might expect this antibody to also selectively bind 
solubilized receptors. To test this, we coupled purified TR-9 
to Sepharose, and incubated the TR-9-Sepharose with 3(3 
cholamidopropyl)dimethylammonio-l-propanesul  fonate  ex- 
tracts of NIL cells, and eluted any bound material with low 
pH and high salt buffer or with potassium isothiocyanate. As 
shown in Table II, material that selectively adsorbed to this 
column retained ~I-thrombin-binding activity with approxi- 
mately a  10-fold higher specific activity than nonadsorbed 
material. SDS gels of this material indicate the presence of 
three major proteins that migrate at approximately 52,000, 
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Figure 4. Effect of purified TR-9 monoclonal IgM on stimulation 
of  [3H]thymidine incorporation  by  alpha-thrombin.  Quiescent 
serum-free cultures of NIL hamster fibroblasts were incubated at 
37~  for 23 h with increasing concentrations of purified TR-9 (the 
IgM fraction isolated from TR-9 ascites) in the presence (A) or ab- 
sence (e) of thrombin (125 ng/ml) before a l-h pulse with [methyl- 
3H]thymidine and determination of acid-precipitable radioactivity. 
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Figure 5.  Stimulation of [3I-I]thymidine  incorporation by purified 
TR-9  monoclonal  IgM  in  combination  with  gamma-thrombin. 
Quiescent cultures of hamster fibroblasts were incubated for 23 h 
with the indicated concentrations of purified TR-9 either with (e) 
or without (o) gamma-thrombin (0.5 ~tg/ml) before a  1-h pulse 
with  [methyl-3H]thymidine. The amount of radioactivity  in the 
acid-precipitable material was determined. 
105,000,  and  150,000  Mr  (Fig.  3).  Since previous studies 
have demonstrated ~25I-thrombin cross-linking to molecules 
of 50,000 and 150,000 Mr (17, 43, 56), it is possible that both 
150,000- and 52,000-Mr peptides have thrombin-binding do- 
mains that might also be recognized by TR-9. Indeed, immu- 
noblots of whole cell extracts and material eluting from TR-9- 
Sepharose have shown TR-9 binding to both the 150,000-Mr 
band and more prominently to the 52,000-Mr band.  Most 
important for our present characterization, it appears that 
TR-9 does not bind other molecules that are known to bind 
thrombin such as  PN (46,000 Mr)  (2) or thrombomodulin 
(96,000 Mr) (26). 
Mitogenic Potential of TR-9 Monoclonal Antibody 
Since TR-9 recognizes thrombin receptors and could effec- 
tively compete for up to 100% of  thrombin binding, we deter- 
mined if this antibody could also block the biological effects 
of thrombin. As shown in Fig. 4, the addition of TR-9-IgM 
by itself does not initiate DNA synthesis in cultures of fibro- 
blastic cells at concentrations up to 4  nM.  Interestingly, if 
TR-9 is added to cells with concentrations of  thrombin previ- 
ously shown to be half-maximal for initiating DNA synthesis 
under these conditions (20), there is no inhibition of throm- 
bin mitogenic activity (Fig. 4). Rather, TR-9-IgM appears to 
enhance thrombin  stimulation  of thymidine incorporation 
from a 7-fold stimulation (by thrombin alone) to an ll-fold 
stimulation with thrombin in the presence of 4  nM TR-9. 
Thus, unlike some antibodies that produce inhibitory effects 
by limiting the interaction of growth factors with their recep- 
tors (27, 42), TR-9 appears to enhance this initiation. This 
suggested  that  TR-9  interaction  with  thrombin  receptors 
might  be  generating  receptor  occupancy-related  signals, 
which are required for thrombin mitogenesis. 
To determine if TR-9 binding to the receptors was generat- 
ing receptor occupancy-dependent signals,  TR-9-IgM was 
added to cells together with gamma-thrombin, which retains 
enzymic activity, but does not bind to cells with high affinity. 
As  shown  in  Fig.  5,  neither  TR-9  nor  gamma-thrombin 
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Figure 6. Stimulation of [3H]thymidine incorporation 
by purified  TR-9  monoclonal  IgM  in combination 
with PMA. Quiescent cultures of hamster fibroblasts 
were incubated for 23 h with indicated concentrations 
of purified TR-9 either with (e) or without (o) PMA 
(25 ng/ml) before a 1-h pulse with [methyl-3H]thymi  - 
dine. The amount of radioactivity in the acid-precipi- 
table material was determined. 
stimulated thymidine incorporation by themselves, but the 
combination causes a threefold stimulation of thymidine in- 
corporation which is nearly equivalent to that seen with com- 
binations of gamma-thrombin  and DIP-thrombin (20). 
The above results indicate that the TR-9 antibody behaves 
like DIP-thrornbin in that it fulfills the requirement for high 
affinity receptor interaction  in the generation of mitogenic 
signals. TR-9 interaction with the receptor, however, could 
alter the receptor conformation allowing gamma-thrombin 
to generate both enzymic and receptor occupancy-related 
signals.  Recent stu~es in our laboratory have shown that 
PMA or dioctanoylglycerol, which activate protein kinase C, 
can stimulate DNA synthesis in the presence of receptor- 
saturating concentrations of DIP-thrombin (31). Thus, acti- 
vation of protein kinase C appears to mimic mitogenic sig- 
nals  stimulated  by gamma-thrombin.  If TR-9  were truly 
generating mitogenic signals itself, we predicted that combi- 
nations of TR-9 and PMA should be equally as effective as 
TR-9 and gamma-thrombin  in stimulating  DNA synthesis. 
As shown in Fig. 6, 25 ng/ml of PMA by itself has little, 
if any, effect on DNA synthesis, but when added to cultures 
together with TR-9-IgM there is a synergistic initiation com- 
parable to that achieved with intact alpha-thrombin or to the 
combination  of DIP-  and  gamma-thrombin.  In  this  case, 
there were no active thrombin molecules present to provide 
mitogenic signals. Thus, the TR-9 monoclonal antibody in- 
teraction  with thrombin  receptors  alone  generates  signals 
that are necessary, and in the presence of PMA, sufficient to 
commit ceils to enter a proliferative cycle. 
Discussion 
To better characterize the high affinity receptor for thrombin 
and its involvement in initiation of cell proliferation we pre- 
pared and selected a monoclonal antibody to this receptor 
and tested its effect on thrombin mitogenesis. The selected 
antibody, designated TR-9, inhibits from 80 to 100% of the 
specific esI-thrombin binding to fibroblasts, has an immu- 
nofluorescent-staining pattern indistinguishable from that of 
thrombin binding, binds to the same number of sites as does 
thrombin, and selectively affinity purifies a putative recep- 
tor  complex which  retains  the  ability  to  bind  t25I-throm- 
bin. Thus, this antibody clearly recognizes the high affinity 
thrombin receptor.  By itself, TR-9 did not stimulate DNA 
synthesis nor block stimulation by alpha-thrombin.  Instead, 
it enhanced stimulation  by half-maximal  concentrations of 
alpha-thrombin.  Moreover,  in  combination  with  gamma- 
thrombin  or  PMA,  TR-9  stimulated  DNA  synthesis  to a 
degree nearly equivalent to that achieved by active alpha- 
thrombin. 
These results with TR-9 monoclonal antibody are consis- 
tent with the "double signal  hypothesis" model previously 
proposed to explain the mechanism of thrombin mitogenesis 
(18). Previous studies from our laboratory have shown that 
cell proliferation  can be initiated  by the addition  of DIP- 
thrombin,  which  binds  to  thrombin  receptors  with  high 
affinity,  and gamma-thrombin,  which does not interact with 
high affinity,  but retains its full esterase activity (20). In the 
present studies, addition of TR-9-IgM and proteolytically ac- 
tive gamma-thrombin or PMA, which appears to mimic the 
signal generated by proteolysis (31), stimulated DNA synthe- 
sis to levels comparable to those achieved with DIP-thrombin 
and  gamma-thrombin.  This  indicates  that  these combina- 
tions provide all signals necessary to stimulate mitogenesis. 
Thus, TR-9 binding is capable of generating the high affinity 
occupancy dependent mitogenic signals. 
The similarity in action of DIP-thrombin and TR-9-IgM 
which, molecularly, are similar only in their ability to bind 
the thrombin receptor,  further  indicates the importance of 
the thrombin receptor in the initiation of cell proliferation. 
Other investigators suggest that occupancy of the thrombin 
receptor  is not  necessary  for  mitogenic  stimulation  (39). 
They report a subclone of Chinese hamster fibroblasts (11C- 
9) that are highly responsive to thrombin but exhibit little 
high affinity t25I-thrombin binding.  Our preliminary results 
show that  these  cells have  large  numbers  of low affinity 
thrombin receptors that also bind the TR-9 monoclonal anti- 
body. It therefore seems likely that these receptors may be 
altered in some way to cause a lower affinity of |~I-throm- 
bin binding. This same alteration (perhaps a conformational 
change) may result in constitutive activation of certain re- 
quired signals normally generated by high affinity receptor 
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help solve this apparent  conflict. 
Other anti-growth factor  receptor monoclonal and poly- 
clonal  antibodies  have  been  generated  and  studied  to de- 
termine their ability  to mediate growth effects of the cor- 
responding  growth  factors.  In  some  cases,  antireceptor 
antibodies inhibit both receptor binding and stimulation of 
DNA synthesis by these growth factors (27, 32, 49). In con- 
trast anti-EGF receptor antibody  2G2IgM inhibits the bind- 
ing of ~25I-EGF to its receptors but induces "EGF-like" re- 
sponses including morphological changes, stimulation of the 
EGF receptor-specific protein kinase, and mitogenesis (51). 
In these and other studies, most antibodies capable of gener- 
ating  mitogenic signals appear  to be multivalent IgM anti- 
bodies, whereas, most IgGs have been inactive. It is possible 
that the decavalent  IgM antibodies have  lower dissociation 
constants  and/or are  better  able to cross-link receptors to 
generate necessary changes in the density or conformation 
of the receptors. 
Interestingly,  TR-9  monoclonal  antibodies  used  in  this 
study also belong to the IgM class. These antibodies may 
thus  cross-link  or  perturb  thrombin  receptors  to  activate 
mitogenic signals. We have postulated that binding of throm- 
bin, DIP-thrombin or TR-9 causes a conformational change 
in the receptor that gives rise to other events, which include 
a transient  increase in intracellular cAMP (18, 32).  Indeed, 
our preliminary results indicate that TR-9-IgM also is capa- 
ble of causing a transient increase in intracellular cAMP. Ad- 
dition of cAMP derivatives to these cells, however, cannot 
substitute  for DIP-thrombin or TR-9.  Thus, the interaction 
of these molecules with the receptor must also generate addi- 
tional signals. 
Thrombin stimulates a number of additional events that 
play a  role in thrombin mitogenesis.  Thrombin stimulates 
turnover of phosphoinositides, release of inositol phosphates 
(19),  and activates  Na+/H  § exchange (52, 53).  These signal 
events, however, appear to be generated  by active thrombin 
proteolysis rather than receptor occupancy since they can be 
stimulated by gamma-thrombin but not by DIP-thrombin (18, 
49,  52).  Since  phosphoinositide  turnover  releases  diacyl- 
glycerol which can activate protein kinase C and protein ki- 
nase C activation  by PMA has been implicated in Na§  + 
antiport  activation  (9), we postulated that activation  of pro- 
tein kinase C may play a crucial role in thrombin mitogene- 
sis. We have now shown that PMA can substitute  for enzy- 
matically active alpha-  or gamma-thrombin  in stimulating 
cell proliferation when thrombin receptors are occupied by 
TR-9-IgM or by DIP-thrombin (20).  In the present experi- 
ments, PMA treatment also appears to reduce the concentra- 
tion of TR-9 necessary to complete mitogenic signals relative 
to that  required  when cells  are  incubated  with TR-9 plus 
gamma-thrombin.  This may indicate that PMA is a much 
better activator of protein kinase C or that the PMA-induced 
protein kinase C activation  triggers  other events that either 
alter the affinity  of the receptor for antibody interaction  or 
the efficiency of receptor-mediated signal transduction. 
Although the mechanism by which receptor occupancy or 
proteolytic cleavage stimulates mitogenic signal events is not 
yet clear, the discovery that monoclonal antibodies to throm- 
bin receptors by themselves can generate mitogenic signals 
suggests that some of these signals can be generated  simply 
by perturbing the conformation of the receptor. Experiments 
are presently underway to use these monoclonal antibodies 
to purify and further characterize the thrombin receptor to 
better understand this process. 
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